110 related articles for article (PubMed ID: 26246179)
1. Should risk-reducing surgery in women from hereditary breast ovarian cancer families be confined to removal of the fallopian tubes with ovarian conservation?
Snyder CL; Casey MJ; Lynch HT
Womens Health (Lond); 2015 Jul; 11(4):423-7. PubMed ID: 26246179
[No Abstract] [Full Text] [Related]
2. Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery.
Rabban JT; Garg K; Crawford B; Chen LM; Zaloudek CJ
Am J Surg Pathol; 2014 Jun; 38(6):729-42. PubMed ID: 24820399
[TBL] [Abstract][Full Text] [Related]
3. [Genetical aspects of surgical treatment in patients with hereditary breast cancer].
Bit-Sava EM
Vestn Khir Im I I Grek; 2014; 173(5):27-30. PubMed ID: 25823331
[TBL] [Abstract][Full Text] [Related]
4. Health care provider recommendations for reducing cancer risks among women with a BRCA1 or BRCA2 mutation.
Metcalfe KA; Kim-Sing C; Ghadirian P; Sun P; Narod SA
Clin Genet; 2014 Jan; 85(1):21-30. PubMed ID: 23859469
[TBL] [Abstract][Full Text] [Related]
5. Rates of risk-reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers.
Laitman Y; Vaisman Y; Feldman D; Helpman L; Gitly M; Paluch Shimon S; Berger R; Cohen L; Narod SA; Friedman E
Clin Genet; 2014 Jan; 85(1):68-71. PubMed ID: 23517234
[TBL] [Abstract][Full Text] [Related]
6. The frequency and outcome of breast cancer risk-reducing surgery in Finnish BRCA1 and BRCA2 mutation carriers.
Koskenvuo L; Svarvar C; Suominen S; Aittomäki K; Jahkola T
Scand J Surg; 2014 Mar; 103(1):34-40. PubMed ID: 24177987
[TBL] [Abstract][Full Text] [Related]
7. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers.
Carcangiu ML; Radice P; Manoukian S; Spatti G; Gobbo M; Pensotti V; Crucianelli R; Pasini B
Int J Gynecol Pathol; 2004 Jan; 23(1):35-40. PubMed ID: 14668548
[TBL] [Abstract][Full Text] [Related]
8. ACOG Practice Bulletin No. 89. Elective and risk-reducing salpingo-oophorectomy.
ACOG
Obstet Gynecol; 2008 Jan; 111(1):231-41. PubMed ID: 18165419
[No Abstract] [Full Text] [Related]
9. Challenging and complex decisions in the management of the BRCA mutation carrier.
Stan DL; Shuster LT; Wick MJ; Swanson CL; Pruthi S; Bakkum-Gamez JN
J Womens Health (Larchmt); 2013 Oct; 22(10):825-34. PubMed ID: 23987739
[TBL] [Abstract][Full Text] [Related]
10. Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1/2 mutation carriers.
Kenkhuis MJ; de Bock GH; Elferink PO; Arts HJ; Oosterwijk JC; Jansen L; Mourits MJ
Maturitas; 2010 Jul; 66(3):310-4. PubMed ID: 20409655
[TBL] [Abstract][Full Text] [Related]
11. Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations.
Rabban JT; Crawford B; Chen LM; Powell CB; Zaloudek CJ
Am J Surg Pathol; 2009 Jan; 33(1):111-9. PubMed ID: 18830124
[TBL] [Abstract][Full Text] [Related]
12. Müllerian intra-abdominal carcinomatosis in hereditary breast ovarian cancer syndrome: implications for risk-reducing surgery.
Casey MJ; Colanta AB
Fam Cancer; 2016 Jul; 15(3):371-84. PubMed ID: 26875157
[TBL] [Abstract][Full Text] [Related]
13. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
[TBL] [Abstract][Full Text] [Related]
14. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing.
Skytte AB; Gerdes AM; Andersen MK; Sunde L; Brøndum-Nielsen K; Waldstrøm M; Kølvraa S; Crüger D
Clin Genet; 2010 Apr; 77(4):342-9. PubMed ID: 20059483
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of genetic testing for BRCA1 and BRCA2 mutations in Austria.
Singer CF; Muhr D; Rappaport C; Tea MK; Gschwantler-Kaulich D; Fink-Retter A; Pfeiler G; Berger A; Sun P; Narod SA
Clin Genet; 2014 Jan; 85(1):72-5. PubMed ID: 23772696
[TBL] [Abstract][Full Text] [Related]
16. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
17. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
[TBL] [Abstract][Full Text] [Related]
18. Risk-reducing salpingo-oophorectomy for BRCA mutation carriers.
Haldar K; Crawford R
Maturitas; 2010 Nov; 67(3):290. PubMed ID: 20869823
[No Abstract] [Full Text] [Related]
19. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
20. Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers.
Fakkert IE; Mourits MJ; Jansen L; van der Kolk DM; Meijer K; Oosterwijk JC; van der Vegt B; Greuter MJ; de Bock GH
Cancer Prev Res (Phila); 2012 Nov; 5(11):1291-7. PubMed ID: 23009828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
